Are Medical Stocks Lagging Bioventus (BVS) This Year?
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
BVS - Bioventus Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.33
DETAILS
HIGH:
$19.00
LOW:
$18.00
MEDIAN:
$18.00
CONSENSUS:
$18.33
UPSIDE:
34.29%
Stock News
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Is Bioventus (BVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Bioventus Q2 Earnings Call Highlights
Bioventus NASDAQ: BVS reported second-quarter 2026 revenue growth of 4% and reiterated its full-year financial outlook, citing double-digit expansion in its Pain Treatments business, continued debt reduction and increased investment in platelet-rich plasma, peripheral nerve stimulation, Ultrasonics and international operations.
Bioventus (BVS) Q2 Earnings Meet Estimates
Bioventus (BVS) came out with quarterly earnings of $0.22 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.21 per share a year ago.
Bioventus Reports Second Quarter Financial Results
DURHAM, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today reported financial results for the three and six months ended June 27, 2026.
Bioventus (BVS) to Report Q2 Results: Wall Street Expects Earnings Growth
Bioventus (BVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bioventus to Report Second Quarter of Fiscal Year 2026 Financial Results on August 5, 2026
DURHAM, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2026 before the market opens on Wednesday, August 5, 2026.
Is Bioventus (BVS) Stock Outpacing Its Medical Peers This Year?
Here is how Bioventus (BVS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Does Bioventus (BVS) Have the Potential to Rally 28.92% as Wall Street Analysts Expect?
The consensus price target hints at a 28.9% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bioventus (BVS) Upgraded to Buy: Here's Why
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice
Does Bioventus (BVS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know
The mean of analysts' price targets for Bioventus (BVS) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade)
Bioventus Inc. develops medical devices and biologics for orthopedic recovery and pain relief. I previously rated it a 'Hold' due to debt, competition, weak cash flow, and valuation concerns despite strong Q2 2024 growth. BVS has recently outperformed the S&P 500 and medtech ETFs, with a breakout driven by favorable regulatory developments.
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
3 Top Breakout Stocks to Snap Up for Big Upside in July 2026
FA, BVS and OOMA emerged as July breakout stock picks after meeting momentum and price-based screens designed to spot potential upside.
Should Value Investors Buy Bioventus (BVS) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Price Targets
Bioventus price target raised to $19 from $15 at Canaccord
$19.00
(was $14.26)
Canaccord Genuity
Bioventus price target raised to $18 from $16 at Craig-Hallum
$18.00
(was $13.87)
Craig-Hallum
Bioventus price target raised to $18 from $14 at Barrington
$18.00
(was $15.26)
Barrington
Canaccord Reiterates Buy Rating on Bioventus Inc (BVS)
$15.00
(was $8.60)
Caitlin Cronin
·
Canaccord Genuity
Bioventus initiated with an Outperform at Barrington
$13.00
(was $8.51)
Barrington
Bioventus price target lowered to $15 from $17 at Craig-Hallum
$15.00
(was $6.20)
Chase Knickerbocker
·
Craig-Hallum
Canaccord Genuity Reiterates Buy Rating on Bioventus Inc (BVS)
$12.00
(was $11.79)
Caitlin Cronin
·
Canaccord Genuity
Bioventus price target raised to $12 from $9 at Craig-Hallum
$12.00
(was $8.25)
Chase Knickerbocker
·
Craig-Hallum
Bioventus Inc (BVS) PT Raised to $8 at Canaccord Genuity
$8.00
(was $5.12)
William Plovanic
·
Canaccord Genuity
Bioventus Inc (BVS) PT Raised to $9 at Craig-Hallum
$9.00
(was $5.29)
Alex Nowak
·
Craig-Hallum
Goldman Sachs Maintains Neutral on Bioventus, Lowers Price Target to $2.5
$2.50
(was $1.91)
Goldman Sachs